- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
St. Leo Today
By the People, for the People
Celcuity Appoints Charles Romp to its Board of Directors
Celcuity (NASDAQ:CELC) announces new board member with extensive commercial experience in oncology
Published on Feb. 12, 2026
Got story updates? Submit your updates here. ›
Celcuity Inc., a clinical-stage biotechnology company, has announced the appointment of Charles Romp to its Board of Directors. Romp is currently the Chief Executive Officer of Secura Bio and previously served as Executive Vice President of Commercial U.S. at Seagen, Inc., where he oversaw the growth and expansion of several oncology therapies.
Why it matters
Romp's extensive experience in the commercialization of oncology therapies will be valuable as Celcuity advances its lead therapeutic candidate, gedatolisib, through late-stage clinical trials and towards potential regulatory approval and commercialization.
The details
Romp previously held several senior sales leadership positions at Genentech, where he was responsible for oncology and immunology products including Avastin, Rituxan, and Xolair. At Seagen, he was a member of the Executive Committee and oversaw the company's entire commercial organization before its sale to Pfizer. Romp received a Bachelor of Arts from the University of Florida and an MBA from Saint Leo University.
- Celcuity announced Romp's appointment to the Board of Directors on February 12, 2026.
The players
Charles Romp
Chief Executive Officer of Secura Bio and former Executive Vice President of Commercial U.S. at Seagen, Inc.
Celcuity Inc.
A clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications.
Seagen, Inc.
An integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of oncology therapies.
Genentech, Inc.
A biotechnology company that develops and commercializes medicines to treat patients with serious or life-threatening medical conditions.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
Celcuity's appointment of Charles Romp, an experienced commercial leader in the oncology space, to its Board of Directors signals the company's focus on advancing its lead therapeutic candidate, gedatolisib, towards potential regulatory approval and commercialization.
